With rapid advances in recombinant DNA and protein engineering technologies, therapeutic fusion proteins have emerged as a new option for biologics with improved pharmacokinetic stability and enhanced capability to act on two or more molecular targets. Fusion proteins have also facilitated the development of new vaccines and gene and cell therapy drugs to address unmet clinical challenges.
This whitepaper identifies some major trends in fusion protein drug R&D that may help to predict future development and pinpoint opportunities for biologics applications in the treatment of various diseases.
Download the whitepaper to explore all these trends identified through the collaboration between Analytics Experts at CAS and National Science Library of The Chinese Academy of Sciences.